Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
Status:
New, Temporarily Closed
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCT#03660826
NRG-GY012 will suspend to accrual effective 02/04/19 due to a planned formal safety review.
